Neurological Disorder Drugs Market 2027 By Drug Type, Disease Type, Distribution Channel | The Insight Partners

Neurological Disorder Drugs Market to 2027 - Global Analysis and Forecasts by Drug Type (Antipsychotic, Antiepileptic, Anticholinergic, Analgesics, Hypnotic and Sedative, Anticoagulants, Antihypertensive); Disease Type (Epilepsy, Parkinson's disease, Alzheimer's disease, Cerebrovascular Disease, Multiple Sclerosis); Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies.)

Report Code: TIPRE00004605 | No. of Pages: 150 | Category: Pharmaceuticals | Status: Upcoming
MARKET INTRODUCTION
Neurological Disorders are associated with dysfunction in any part of the brain or nervous system resulting in physical or psychological damage. Various types of neurological drugs are available in the market such as antipsychotic, antiepileptic, anticholinergic and analgesics for the treatments of neurological disorders.

MARKET DYNAMICS
The Neurological Disorder Drugs market is anticipated to grow in the forecast period owing to driving factors such as increasing awareness associated with early disease diagnosis, rise in cerebral stroke, rise in severe disorders such as Alzheimer's epilepsy and Parkinsonism, sedentary lifestyle, increasing stress and depression etc. Nevertheless, the stringent and lengthy drug approvals procedures and expensive r&d cost is expected to hamper the growth of the market during the forecast period.

MARKET SCOPE
The "Global Neurological Disorder Drugs Market Analysis to 2027" is a specialized and in-depth study of the pharmaceuticals industry with a special focus on the global market trend analysis. The report aims to provide an overview of Neurological Disorder Drugs market with detailed market segmentation by Drug Type, Disease Type, Distribution Channel and geography. The global Neurological Disorder Drugs market is expected to witness high growth during the forecast period. The report provides key statistics on the market status of the leading Neurological Disorder Drugs market players and offers key trends and opportunities in the market.

MARKET SEGMENTATION
The global Neurological Disorder Drugs market is segmented on the basis of Drug Type, Disease Type and Distribution Channel. Based on Drug type the market is segmented into Antipsychotic, Antiepileptic, Anticholinergic, Analgesics, Hypnotic and Sedative, Anticoagulants, Antihypertensive. Based on Disease Type the market is segmented into Epilepsy, Parkinson's disease, Alzheimer's disease, Cerebrovascular Disease, Multiple Sclerosis. Based on Distribution Channel the market is segmented into Hospital Pharmacies, Retail Pharmacies, Online Pharmacies.
REGIONAL FRAMEWORK
The report provides a detailed overview of the industry including both qualitative and quantitative information. It provides overview and forecast of the global Neurological Disorder Drugs market based on various segments. It also provides market size and forecast estimates from year 2017 to 2027 with respect to five major regions, namely; North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South & Central America. The Neurological Disorder Drugs market by each region is later sub-segmented by respective countries and segments. The report covers analysis and forecast of 18 countries globally along with current trend and opportunities prevailing in the region.

The report analyzes factors affecting Neurological Disorder Drugs market from both demand and supply side and further evaluates market dynamics effecting the market during the forecast period i.e., drivers, restraints, opportunities, and future trend. The report also provides exhaustive PEST analysis for all five regions namely; North America, Europe, APAC, MEA and South & Central America after evaluating political, economic, social and technological factors effecting the Neurological Disorder Drugs market in these regions.

MARKET PLAYERS
The reports cover key developments in the Neurological Disorder Drugs Market as organic and inorganic growth strategies. Various companies are focusing on organic growth strategies such as product launches, product approvals and others such as patents and events. Inorganic growth strategies activities witnessed in the market were acquisitions, and partnership & collaborations. These activities have paved way for expansion of business and customer base of market players. The market payers from Neurological Disorder Drugs Market are anticipated to lucrative growth opportunities in the future with the rising demand for Neurological Disorder Drugs in the global market. Below mentioned is the list of few companies engaged in the Neurological Disorder Drugs market.

The report also includes the profiles of key Neurological Disorder Drugs Market companies along with their SWOT analysis and market strategies. In addition, the report focuses on leading industry players with information such as company profiles, components and services offered, financial information of last 3 years, key development in past five years.
  • Neurocrine Biosciences, Inc.,
  • Pfizer Inc.,
  • Biogen Inc.,
  • Teva Pharmaceutical Industries Ltd.,
  • AcelRx Pharmaceuticals, Inc.,
  • Eli Lilly and Company,
  • Adamas Pharmaceuticals, Inc.,
  • BioMarin Pharmaceutical Inc
  • AstraZeneca plc,
  • Novartis International AG.
The Insight Partner's dedicated research and analysis team consist of experienced professionals with advanced statistical expertise and offer various customization options in the existing study.

TABLE OF CONTENTS

1. INTRODUCTION
1.1. SCOPE OF THE STUDY
1.2. THE INSIGHT PARTNERS RESEARCH REPORT GUIDANCE
1.3. MARKET SEGMENTATION
1.3.1 Neurological Disorder Drugs Market - By Drug Type
1.3.2 Neurological Disorder Drugs Market - By Disease Type
1.3.3 Neurological Disorder Drugs Market - By Distribution Channel
1.3.4 Neurological Disorder Drugs Market - By Region
1.3.4.1 By Country
2. KEY TAKEAWAYS
3. RESEARCH METHODOLOGY
4. NEUROLOGICAL DISORDER DRUGS MARKET LANDSCAPE
4.1. OVERVIEW
4.2. PEST ANALYSIS
4.2.1 North America - Pest Analysis
4.2.2 Europe - Pest Analysis
4.2.3 Asia-Pacific - Pest Analysis
4.2.4 Middle East and Africa - Pest Analysis
4.2.5 South and Central America - Pest Analysis
4.3. EXPERT OPINIONS
5. NEUROLOGICAL DISORDER DRUGS MARKET - KEY MARKET DYNAMICS
5.1. KEY MARKET DRIVERS
5.2. KEY MARKET RESTRAINTS
5.3. KEY MARKET OPPORTUNITIES
5.4. FUTURE TRENDS
5.5. IMPACT ANALYSIS OF DRIVERS AND RESTRAINTS
6. NEUROLOGICAL DISORDER DRUGS MARKET - GLOBAL MARKET ANALYSIS
6.1. NEUROLOGICAL DISORDER DRUGS - GLOBAL MARKET OVERVIEW
6.2. NEUROLOGICAL DISORDER DRUGS - GLOBAL MARKET AND FORECAST TO 2027
6.3. MARKET POSITIONING/MARKET SHARE
7. NEUROLOGICAL DISORDER DRUGS MARKET - REVENUE AND FORECASTS TO 2027 - DRUG TYPE
7.1. OVERVIEW
7.2. DRUG TYPE MARKET FORECASTS AND ANALYSIS
7.3. ANTIPSYCHOTIC
7.3.1. Overview
7.3.2. Antipsychotic Market Forecast and Analysis
7.4. ANTIEPILEPTIC
7.4.1. Overview
7.4.2. Antiepileptic Market Forecast and Analysis
7.5. ANTICHOLINERGIC
7.5.1. Overview
7.5.2. Anticholinergic Market Forecast and Analysis
7.6. ANALGESICS
7.6.1. Overview
7.6.2. Analgesics Market Forecast and Analysis
7.7. HYPNOTIC AND SEDATIVE
7.7.1. Overview
7.7.2. Hypnotic and Sedative Market Forecast and Analysis
7.8. ANTICOAGULANTS
7.8.1. Overview
7.8.2. Anticoagulants Market Forecast and Analysis
7.9. ANTIHYPERTENSIVE
7.9.1. Overview
7.9.2. Antihypertensive Market Forecast and Analysis
8. NEUROLOGICAL DISORDER DRUGS MARKET - REVENUE AND FORECASTS TO 2027 - DISEASE TYPE
8.1. OVERVIEW
8.2. DISEASE TYPE MARKET FORECASTS AND ANALYSIS
8.3. EPILEPSY
8.3.1. Overview
8.3.2. Epilepsy Market Forecast and Analysis
8.4. PARKINSON'S DISEASE
8.4.1. Overview
8.4.2. Parkinson's disease Market Forecast and Analysis
8.5. ALZHEIMER'S DISEASE
8.5.1. Overview
8.5.2. Alzheimer's disease Market Forecast and Analysis
8.6. CEREBROVASCULAR DISEASE
8.6.1. Overview
8.6.2. Cerebrovascular Disease Market Forecast and Analysis
8.7. MULTIPLE SCLEROSIS
8.7.1. Overview
8.7.2. Multiple Sclerosis Market Forecast and Analysis
9. NEUROLOGICAL DISORDER DRUGS MARKET - REVENUE AND FORECASTS TO 2027 - DISTRIBUTION CHANNEL
9.1. OVERVIEW
9.2. DISTRIBUTION CHANNEL MARKET FORECASTS AND ANALYSIS
9.3. HOSPITAL PHARMACIES
9.3.1. Overview
9.3.2. Hospital Pharmacies Market Forecast and Analysis
9.4. RETAIL PHARMACIES
9.4.1. Overview
9.4.2. Retail Pharmacies Market Forecast and Analysis
9.5. ONLINE PHARMACIES.
9.5.1. Overview
9.5.2. Online Pharmacies. Market Forecast and Analysis
10. NEUROLOGICAL DISORDER DRUGS MARKET REVENUE AND FORECASTS TO 2027 - GEOGRAPHICAL ANALYSIS
10.1. NORTH AMERICA
10.1.1 North America Neurological Disorder Drugs Market Overview
10.1.2 North America Neurological Disorder Drugs Market Forecasts and Analysis
10.1.3 North America Neurological Disorder Drugs Market Forecasts and Analysis - By Drug Type
10.1.4 North America Neurological Disorder Drugs Market Forecasts and Analysis - By Disease Type
10.1.5 North America Neurological Disorder Drugs Market Forecasts and Analysis - By Distribution Channel
10.1.6 North America Neurological Disorder Drugs Market Forecasts and Analysis - By Countries
10.1.6.1 United States Neurological Disorder Drugs Market
10.1.6.1.1 United States Neurological Disorder Drugs Market by Drug Type
10.1.6.1.2 United States Neurological Disorder Drugs Market by Disease Type
10.1.6.1.3 United States Neurological Disorder Drugs Market by Distribution Channel
10.1.6.2 Canada Neurological Disorder Drugs Market
10.1.6.2.1 Canada Neurological Disorder Drugs Market by Drug Type
10.1.6.2.2 Canada Neurological Disorder Drugs Market by Disease Type
10.1.6.2.3 Canada Neurological Disorder Drugs Market by Distribution Channel
10.1.6.3 Mexico Neurological Disorder Drugs Market
10.1.6.3.1 Mexico Neurological Disorder Drugs Market by Drug Type
10.1.6.3.2 Mexico Neurological Disorder Drugs Market by Disease Type
10.1.6.3.3 Mexico Neurological Disorder Drugs Market by Distribution Channel
10.1.6.4 US Neurological Disorder Drugs Market
10.1.6.4.1 US Neurological Disorder Drugs Market by Drug Type
10.1.6.4.2 US Neurological Disorder Drugs Market by Disease Type
10.1.6.4.3 US Neurological Disorder Drugs Market by Distribution Channel
10.2. EUROPE
10.2.1 Europe Neurological Disorder Drugs Market Overview
10.2.2 Europe Neurological Disorder Drugs Market Forecasts and Analysis
10.2.3 Europe Neurological Disorder Drugs Market Forecasts and Analysis - By Drug Type
10.2.4 Europe Neurological Disorder Drugs Market Forecasts and Analysis - By Disease Type
10.2.5 Europe Neurological Disorder Drugs Market Forecasts and Analysis - By Distribution Channel
10.2.6 Europe Neurological Disorder Drugs Market Forecasts and Analysis - By Countries
10.2.6.1 Germany Neurological Disorder Drugs Market
10.2.6.1.1 Germany Neurological Disorder Drugs Market by Drug Type
10.2.6.1.2 Germany Neurological Disorder Drugs Market by Disease Type
10.2.6.1.3 Germany Neurological Disorder Drugs Market by Distribution Channel
10.2.6.2 France Neurological Disorder Drugs Market
10.2.6.2.1 France Neurological Disorder Drugs Market by Drug Type
10.2.6.2.2 France Neurological Disorder Drugs Market by Disease Type
10.2.6.2.3 France Neurological Disorder Drugs Market by Distribution Channel
10.2.6.3 Italy Neurological Disorder Drugs Market
10.2.6.3.1 Italy Neurological Disorder Drugs Market by Drug Type
10.2.6.3.2 Italy Neurological Disorder Drugs Market by Disease Type
10.2.6.3.3 Italy Neurological Disorder Drugs Market by Distribution Channel
10.2.6.4 Spain Neurological Disorder Drugs Market
10.2.6.4.1 Spain Neurological Disorder Drugs Market by Drug Type
10.2.6.4.2 Spain Neurological Disorder Drugs Market by Disease Type
10.2.6.4.3 Spain Neurological Disorder Drugs Market by Distribution Channel
10.2.6.5 United Kingdom Neurological Disorder Drugs Market
10.2.6.5.1 United Kingdom Neurological Disorder Drugs Market by Drug Type
10.2.6.5.2 United Kingdom Neurological Disorder Drugs Market by Disease Type
10.2.6.5.3 United Kingdom Neurological Disorder Drugs Market by Distribution Channel
10.3. ASIA-PACIFIC
10.3.1 Asia-Pacific Neurological Disorder Drugs Market Overview
10.3.2 Asia-Pacific Neurological Disorder Drugs Market Forecasts and Analysis
10.3.3 Asia-Pacific Neurological Disorder Drugs Market Forecasts and Analysis - By Drug Type
10.3.4 Asia-Pacific Neurological Disorder Drugs Market Forecasts and Analysis - By Disease Type
10.3.5 Asia-Pacific Neurological Disorder Drugs Market Forecasts and Analysis - By Distribution Channel
10.3.6 Asia-Pacific Neurological Disorder Drugs Market Forecasts and Analysis - By Countries
10.3.6.1 Australia Neurological Disorder Drugs Market
10.3.6.1.1 Australia Neurological Disorder Drugs Market by Drug Type
10.3.6.1.2 Australia Neurological Disorder Drugs Market by Disease Type
10.3.6.1.3 Australia Neurological Disorder Drugs Market by Distribution Channel
10.3.6.2 China Neurological Disorder Drugs Market
10.3.6.2.1 China Neurological Disorder Drugs Market by Drug Type
10.3.6.2.2 China Neurological Disorder Drugs Market by Disease Type
10.3.6.2.3 China Neurological Disorder Drugs Market by Distribution Channel
10.3.6.3 India Neurological Disorder Drugs Market
10.3.6.3.1 India Neurological Disorder Drugs Market by Drug Type
10.3.6.3.2 India Neurological Disorder Drugs Market by Disease Type
10.3.6.3.3 India Neurological Disorder Drugs Market by Distribution Channel
10.3.6.4 Japan Neurological Disorder Drugs Market
10.3.6.4.1 Japan Neurological Disorder Drugs Market by Drug Type
10.3.6.4.2 Japan Neurological Disorder Drugs Market by Disease Type
10.3.6.4.3 Japan Neurological Disorder Drugs Market by Distribution Channel
10.4. MIDDLE EAST AND AFRICA
10.4.1 Middle East and Africa Neurological Disorder Drugs Market Overview
10.4.2 Middle East and Africa Neurological Disorder Drugs Market Forecasts and Analysis
10.4.3 Middle East and Africa Neurological Disorder Drugs Market Forecasts and Analysis - By Drug Type
10.4.4 Middle East and Africa Neurological Disorder Drugs Market Forecasts and Analysis - By Disease Type
10.4.5 Middle East and Africa Neurological Disorder Drugs Market Forecasts and Analysis - By Distribution Channel
10.4.6 Middle East and Africa Neurological Disorder Drugs Market Forecasts and Analysis - By Countries
10.4.6.1 South Africa Neurological Disorder Drugs Market
10.4.6.1.1 South Africa Neurological Disorder Drugs Market by Drug Type
10.4.6.1.2 South Africa Neurological Disorder Drugs Market by Disease Type
10.4.6.1.3 South Africa Neurological Disorder Drugs Market by Distribution Channel
10.4.6.2 Saudi Arabia Neurological Disorder Drugs Market
10.4.6.2.1 Saudi Arabia Neurological Disorder Drugs Market by Drug Type
10.4.6.2.2 Saudi Arabia Neurological Disorder Drugs Market by Disease Type
10.4.6.2.3 Saudi Arabia Neurological Disorder Drugs Market by Distribution Channel
10.4.6.3 U.A.E Neurological Disorder Drugs Market
10.4.6.3.1 U.A.E Neurological Disorder Drugs Market by Drug Type
10.4.6.3.2 U.A.E Neurological Disorder Drugs Market by Disease Type
10.4.6.3.3 U.A.E Neurological Disorder Drugs Market by Distribution Channel
10.5. SOUTH AND CENTRAL AMERICA
10.5.1 South and Central America Neurological Disorder Drugs Market Overview
10.5.2 South and Central America Neurological Disorder Drugs Market Forecasts and Analysis
10.5.3 South and Central America Neurological Disorder Drugs Market Forecasts and Analysis - By Drug Type
10.5.4 South and Central America Neurological Disorder Drugs Market Forecasts and Analysis - By Disease Type
10.5.5 South and Central America Neurological Disorder Drugs Market Forecasts and Analysis - By Distribution Channel
10.5.6 South and Central America Neurological Disorder Drugs Market Forecasts and Analysis - By Countries
10.5.6.1 Brazil Neurological Disorder Drugs Market
10.5.6.1.1 Brazil Neurological Disorder Drugs Market by Drug Type
10.5.6.1.2 Brazil Neurological Disorder Drugs Market by Disease Type
10.5.6.1.3 Brazil Neurological Disorder Drugs Market by Distribution Channel
10.5.6.2 Argentina Neurological Disorder Drugs Market
10.5.6.2.1 Argentina Neurological Disorder Drugs Market by Drug Type
10.5.6.2.2 Argentina Neurological Disorder Drugs Market by Disease Type
10.5.6.2.3 Argentina Neurological Disorder Drugs Market by Distribution Channel
11. INDUSTRY LANDSCAPE
11.1. MERGERS AND ACQUISITIONS
11.2. AGREEMENTS, COLLABORATIONS AND JOIN VENTURES
11.3. NEW PRODUCT LAUNCHES
11.4. EXPANSIONS AND OTHER STRATEGIC DEVELOPMENTS
12. NEUROLOGICAL DISORDER DRUGS MARKET, KEY COMPANY PROFILES
12.1. NEUROCRINE BIOSCIENCES, INC
12.1.1. Key Facts
12.1.2. Business Description
12.1.3. Products and Services
12.1.4. Financial Overview
12.1.5. SWOT Analysis
12.1.6. Key Developments
12.2. PFIZER INC
12.2.1. Key Facts
12.2.2. Business Description
12.2.3. Products and Services
12.2.4. Financial Overview
12.2.5. SWOT Analysis
12.2.6. Key Developments
12.3. BIOGEN INC
12.3.1. Key Facts
12.3.2. Business Description
12.3.3. Products and Services
12.3.4. Financial Overview
12.3.5. SWOT Analysis
12.3.6. Key Developments
12.4. TEVA PHARMACEUTICAL INDUSTRIES LTD
12.4.1. Key Facts
12.4.2. Business Description
12.4.3. Products and Services
12.4.4. Financial Overview
12.4.5. SWOT Analysis
12.4.6. Key Developments
12.5. ACELRX PHARMACEUTICALS, INC
12.5.1. Key Facts
12.5.2. Business Description
12.5.3. Products and Services
12.5.4. Financial Overview
12.5.5. SWOT Analysis
12.5.6. Key Developments
12.6. ELI LILLY AND COMPANY
12.6.1. Key Facts
12.6.2. Business Description
12.6.3. Products and Services
12.6.4. Financial Overview
12.6.5. SWOT Analysis
12.6.6. Key Developments
12.7. ADAMAS PHARMACEUTICALS, INC
12.7.1. Key Facts
12.7.2. Business Description
12.7.3. Products and Services
12.7.4. Financial Overview
12.7.5. SWOT Analysis
12.7.6. Key Developments
12.8. BIOMARIN PHARMACEUTICAL INC
12.8.1. Key Facts
12.8.2. Business Description
12.8.3. Products and Services
12.8.4. Financial Overview
12.8.5. SWOT Analysis
12.8.6. Key Developments
12.9. ASTRAZENECA PLC
12.9.1. Key Facts
12.9.2. Business Description
12.9.3. Products and Services
12.9.4. Financial Overview
12.9.5. SWOT Analysis
12.9.6. Key Developments
12.10. NOVARTIS INTERNATIONAL AG.
12.10.1. Key Facts
12.10.2. Business Description
12.10.3. Products and Services
12.10.4. Financial Overview
12.10.5. SWOT Analysis
12.10.6. Key Developments
13. APPENDIX
13.1. ABOUT THE INSIGHT PARTNERS
13.2. GLOSSARY OF TERMS
The List of Companies

- Neurocrine Biosciences, Inc.,
- Pfizer Inc.,
- Biogen Inc.,
- Teva Pharmaceutical Industries Ltd.,
- AcelRx Pharmaceuticals, Inc.,
- Eli Lilly and Company,
- Adamas Pharmaceuticals, Inc.,
- BioMarin Pharmaceutical Inc
- AstraZeneca plc,
- Novartis International AG.